CIA - Collegium Internationionale Allergologicum
32nd Symposium of the Collegium Internationale Allergologicum
 

Late Breaking Abstract Submission Guidelines

Click here to submit Abstract

Late Breaking Deadline for Submission – 1 June 2018

Word Limit – 350 words

The Collegium Internationale Allergologicum invites members and non-members to submit abstracts for review for poster or oral presentation at the 32nd Symposium in Mallorca, Spain. 

The following guidelines address key factors that the Collegium Internationale Allergologicum Organizing Committee considers when reviewing abstracts. Attention to these details will assist the Committee in making their decision.

  1. Abstracts should contain a concise statement of the problem under investigation; describe experimental methods used; contain specific findings and data (promises such as “the results to be completed” are not appropriate); and contain conclusions based on the data presented (statistical analyses should be used when appropriate to support the conclusions).
  2. Define all concepts and abbreviations at first use. Do not use abbreviations in the title of the abstract.
  3. Previously published abstracts will NOT be considered.
  4. All abstract presenters will be required to register for the symposium, and pay all registration and travel costs.
  5. Abstract submissions can only be made by Collegium Internationale Allergologicum members, candidates or sponsored non-members.

Abstracts can be submitted in the following categories:

*Please select the category of your abstract:

Category 1: Genomics, and Environmental Factors and Precision Medicine

  • Genomics of allergic disorders and asthma
  • Environmental factors in immune disorders
  • Epidemiology: risk and protective factors in allergy
  • Air pollution: Indoor and outdoor 
  • Climate change, global warming and biodiversity
  • Microbiome and allergies
  • Infection and allergies
  • Proteomics
  • Systems biology and precision Medicine

Category 2: Dendritic Cells, Mast Cells, Monocytes/Macrophages, Neutrophils, Eosinophils, Basophils and Epithelial Cells

Category 3: Lymphocytes and Mediators of Immunoregulation

  • Cytokines and chemokines
  • T-Cells and regulatory T-cells
  • B-Cells and regulatory B-cells
  • NK and iNKT cells
  • ILCs
  • Immunoregulation
  • Adjuvants

Category 4: Food and Drug Allergies and Gastrointestinal Disorders

  • Epidemiology and pathomechanisms
  • Diagnosis
  • Novel therapies
  • Prevention/ Probiotics/ prebiotics/synbiotics

Category 5: Treatment of Asthma, Rhinitis and Atopic Dermatitis

  • Novel Biologics in Asthma
  • Therapies for Rhinitis/Conjunctivitis
  • New Targets in Atopic Dermatitis

Category 6: Urticaria, Angioedema, Anaphylaxis, Mastocytosis and Mast Cell Activation Disorders

Category 7: Allergens and Diagnosis of Allergy

  • Allergens
  • Triggers of allergy
  • Biomarkers of allergy: prognosis, severity and treatment efficacy
  • Diagnostic methodologies

Category 8: Pathophysiology of Allergic Disorders and Inflammation

  • Animal models
  • Mediators of inflammation
  • Immunoglobulins: roles, receptors, regulation
  • Pathophysiology of the allergic response
  • Inflammation: acute/chronic
  • Nerves and Inflammation

Category 9: Treatment of Non-Allergic Immune Disorders

  • Immunomodulation: strategies for prevention and treatment
  • Autoimmune diseases
  • Immunodeficiencies
  • Experimental therapeutics

Category 10: Allergen Specific Immunotherapy

  • Sublingual Immunotherapy (SLIT)
  • Subcutaneous Immunotherapy (SCIT)
  • Oral Immunotherapy (OIT)
  • Novel therapies
    • Synthetic Peptides
    • Modified Allergens & Adjuvants
    • Monoclonal Antibodies
    • Recombinant B-cell epitope vaccines
  • Novel Delivery Systems
    • Liposomes
    • VLP constructs
    • ILIT
    • EPIT
    • Other



© 2018 Collegium Internationale Allergologicum